Peter Schmid

Peter Schmid was the principal investigator of the KEYNOTE-522 trial that established pembrolizumab plus chemotherapy as the standard neoadjuvant and adjuvant regimen for high-risk early triple-negative breast cancer. This landmark trial demonstrated improved pathological complete response rates and event-free survival, leading to FDA approval. He leads translational breast cancer research at Barts Cancer Institute and has contributed to multiple other immunotherapy trials in breast cancer. He is internationally recognized as a leading authority on immunotherapy in triple-negative breast cancer.